About The Study: In this randomized, placebo-controlled clinical trial that included 3,020 patients with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment.
About The Study: In this randomized, placebo-controlled clinical trial that included 3,020 patients with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment.
Authors: Wendy Y. Chen, M.D., of the Dana Farber Cancer Institute in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.4840)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
